Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...
Shares of Novo Nordisk increased after the company withdrew its bid for U.S. weight loss drug maker Metsera, allowing Pfizer to secure a $10 billion deal. This move grants Pfizer entry into the ...
The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...
U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a ...
Discover how DAOs revolutionize drug discovery through decentralized funding, transparency, and community governance.
The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback